A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis

By sjmartinez • October 22, 2022

Tayek JA, Stolz AA, Nguyen DV, Fleischman MW, Donovan JA, Alcorn JM, Chao DC, Asghar A, Morgan TR; Southern California Alcoholic Hepatitis (SCAH) Consortium. A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis. EClinicalMedicine. 2022 Oct 12;54:101689. doi: 10.1016/j.eclinm.2022.101689. PMID: 36267499; PMCID: PMC9576807.

Tags: ACLF, acute kidney injury, acute on chronic liver failure, AH, AKI, alcohol-related hepatitis, Alcoholic hepatitis, common terminology criteria for adverse events, CTCAE, data safety monitoring board, DF, discriminant function, DSMB, FDA, follow-up, food and drug administration, FU, GCSF, General Internal Medicine, granulocyte colony stimulating factor, Harbor UCLA, hepatorenal syndrome, HIV, HRS, human immunodeficiency virus, INR, international normalized ratio, national institute on alcohol abuse and alcoholism, NIAAA, Pegfilgrastim, Phase II, Publications, Randomized clinical trial, SD, SOC, standard deviation, standard of care, WBC, white blood cell count

A Unique Case of a Mildly Symptomatic Patient With Severe Hypokalemia Secondary to Furosemide

Dao KT, Dhillon A, Uddin SS, Eppanapally S, Lai H. A Unique Case of a Mildly Symptomatic Patient With Severe Hypokalemia Secondary to Furosemide. J[...]

Advancements in Spinal Cord Injury Rehabilitation

Eapen BC. Advancements in Spinal Cord Injury Rehabilitation. Phys Med Rehabil Clin N Am. 2025 Feb;36(1):xiii-xiv. doi: 10.1016/j.pmr.2024.09.002. Epub 2024 Oct 18. PMID: 39567042.

Higher-order disease interactions in multimorbidity measurement: marginal benefit over additive disease summation

Wei MY, Tseng CH, Kang AJ. Higher-order disease interactions in multimorbidity measurement: marginal benefit over additive disease summation. J Gerontol A Biol Sci Med Sci.[...]